- Zelira Therapeutics’ (ZLD) latest trial results show almost 70 per cent of patients with autism spectrum disorder achieved moderate therapeutic effect while using HOPE
- The company published a white paper detailing an analysis of real-world data generated from patients using its HOPE treatment
- The cannabinoid-based medicine appeared to be safe, with the majority of patients rated by clinicians as having achieved a moderate therapeutic effect after five months
- The trial data will be used to support the design of future interventional clinical trials with HOPE
- Zelira is up 0.43 per cent, trading at $1.18 per share at 12:15 pm AEST
Zelira Therapeutics’ (ZLD) latest trial results have shown almost 70 per cent of patients with autism spectrum disorder achieved moderate therapeutic effect while using HOPE.
The company published a white paper detailing an analysis of real-world data generated from patients using HOPE.
In November 2020, Zelira entered an agreement with Emyria (EMD) to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD), treated with Zelira’s HOPE product. Under the agreement, Emyria provided Zelira with results collected from patients prescribed a HOPE product.
The average age of patients trying Zelira’s drug was 14 years, with the youngest patient just five years old. Each volunteer used the treatment for an average of 4.8 months.
The cannabinoid-based treatment appeared to be safe, despite 25 adverse events occurring in nine individuals — all of which Zelira said were mild and transient — while some patients were on concomitant medications, including anti-psychotics and serotonin inhibitors.
Almost 70 per cent of patients in the trial were rated by clinicians as having achieved a moderate therapeutic effect after five months taking dosages of HOPE.
Additionally, an effective dosing range was established for both paediatric and adult ASD patients based on the results of this study.
Zelira Therapeutics Managing Director Dr Oludare Odumosu said the results provide additional clinical and regulatory validation for its products.
“Zelira is pleased to share the results from this longitudinal real-world trial because it provides prescribers with empirical information and additional confidence to prescribe HOPE 1,” Dr Odumosu said.
The trial data will be used to support the design of future interventional clinical trials with HOPE.
Zelira was up 0.43 per cent, trading at $1.18 per share at 12:15 pm AEST.